Silence Therapeutics (NASDAQ: SLN) Closed Its Upsized $175 Million Underwritten Public Offering of American Depositary Shares Following the August 10 Phase 2 SANRECO Trial Win in Polycythemia Vera Where Divesiran Achieved 88% Response Versus 19% on Placebo (P<0.0001, 69% Placebo-Adjusted Response Rate); The Offering Priced on August 11 at $13.50 per ADS for 12,962,963 ADSs and the Underwriters (Jefferies, Morgan Stanley, Cantor, and William Blair as Joint Book-Running Managers) Fully Exercised Their 30-Day Overallotment Option for an Additional 1,944,444 ADSs Bringing the Total to 14,907,407 ADSs; The Financing Provides the Capital to Advance Divesiran Into Phase 3 (Planned Initiation H1 2027) Plus Broader Pipeline Progression Including the GalNAc-Conjugated Hepatic-Target siRNA Portfolio Across TMPRSS6, Complement Component 3 (SLN-124/SLN-501), and Other Hepatic Targets
Silence Therapeutics (NASDAQ: SLN) closed its upsized $175 million underwritten public offering of American Depositary Shares (ADSs) following the August 10, 2026 Phase 2 SANRECO trial win in polycythemia vera. Trial anchor: divesiran achieved 88% response versus 19% on placebo (P<0.0001, 69% placebo-adjusted response rate) in 48 phlebotomy-dependent patients over 36 weeks. Offering mechanics: priced August 11 at $13.50 per ADS for 12,962,963 ADSs. The underwriters (Jefferies, Morgan Stanley, Cantor Fitzgerald, and William Blair as joint book-running managers) fully exercised their 30-day overallotment option for an additional 1,944,444 ADSs, bringing the total offering to 14,907,407 ADSs and gross proceeds to approximately $175 million. The financing provides the capital to advance divesiran into Phase 3 (planned initiation H1 2027) plus broader pipeline progression including the GalNAc-conjugated hepatic-target siRNA portfolio across TMPRSS6, complement component 3 (SLN-124/SLN-501), and other hepatic and extrahepatic targets. Divesiran has FDA Fast Track and Orphan Drug designations for polycythemia vera; the transferable-voucher secondary market and the recently completed Arrowhead $215 million Priority Review Voucher purchase provide comparable references for the broader siRNA regulatory-instrument landscape.